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C57BL/6 (H-2b) mice generate type-specific cytolytic T-lymphocyte (CTL) responses to an immunodominant
Kb-restricted epitope, KSPWFTTL located in the membrane-spanning domain of p15TM of AKR/Gross murine
leukemia viruses (MuLV). AKR.H-2b congenic mice, although carrying the responder H-2b major histocompatibility complex (MHC) haplotype, are low responders or nonresponders for AKR/Gross MuLV-specific
CTL, apparently due to the presence of inhibitory AKR.H-2b cells. Despite their expression of viral antigens
and Kb, untreated viable AKR.H-2b spleen cells cause dramatic inhibition of the C57BL/6 (B6) antiviral CTL
response to in vitro stimulation with AKR/Gross MuLV-induced tumor cells. This inhibition is specific
(AKR.H-2b modulator spleen cells do not inhibit allogeneic MHC or minor histocompatibility antigen-specific
CTL production), dependent on direct contact of AKR.H-2b cells in a dose-dependent manner with the
responder cell population, and not due to soluble factors. Here, the mechanism of inhibition of the antiviral
CTL response is shown to depend on Fas/Fas-ligand interactions, implying an apoptotic effect on B6 responder
cells. Although B6.gld (FasL2) responders were as sensitive to inhibition by AKR.H-2b modulator cells as were
B6 responders, B6.lpr (Fas2) responders were largely insensitive to inhibition, indicating that the responder
cells needed to express Fas. A Fas-Ig fusion protein, when added to the in vitro CTL stimulation cultures,
relieved the inhibition caused by the AKR.H-2b cells if the primed responders were from either B6 or B6.gld
mice, indicating that the inhibitory AKR.H-2b cells express FasL. Because of the antigen specificity of the
inhibition, these results collectively implicate a FasL/Fas interaction mechanism: viral antigen-positive
AKR.H-2b cells expressing FasL inhibit antiviral T cells (“veto” them) when the AKR.H-2b cells are recognized.
Consistent with this model, inhibition by AKR.H-2b modulator cells was MHC restricted, and resulted in
approximately a 10- to 70-fold decrease in the in vitro expansion of pCTL/CTL. Both CD81 CTL and CD41 Th
responder cells were susceptible to inhibition by FasL1 AKR.H-2b inhibitory cells as the basis for inhibition.
The CTL response in the presence of inhibitory cells could be restored by several cytokines or agents that have
been shown by others to interfere with activation-induced cell death (e.g., interleukin-2 [IL-2], IL-15, transforming growth factor b, lipopolysaccharide, 9-cis-retinoic acid) but not others (e.g., tumor necrosis factor
alpha). These results raise the possibility that this type of inhibitory mechanism is generalized as a common
strategy for retrovirus infected cells to evade immune T-cell recognition.
It is generally accepted that CD81 CTL play a major role in
host defense against virus infections and the development of
neoplastically transformed cells. On the other hand, viruses,
including retroviruses, and tumors have been selected to exhibit a number of “escape” mechanisms by which immune
system surveillance by specific CTL is avoided. These escape
mechanisms include both strategies to subvert recognition and
lysis by effector CTL that have already been generated, such as
FasL expression by certain tumor cells, and other mechanisms
to inhibit the production of specific CTL. Animal models of
virus infections and tumor development, including CTL responses to MuLV, have been particularly useful in the study of
the generation of CTL responses and thus provide appropriate
systems to examine virus or tumor escape at the level of induction of CTL.
We have previously demonstrated that mice of the H-2b
haplotype, such as B6 mice, can elicit vigorous AKR/Gross
MuLV type-specific CTL responses following in vivo priming

and in vitro restimulation with AKR/Gross MuLV-positive,
H-2b matched tumor cells (16). For these antiviral CTL, an
immunodominant Kb-restricted epitope, KSPWFTTL, derived
from the retroviral p15 TM envelope protein, has been identified (7, 19, 36, 46). The importance of this CTL epitope in
immune system surveillance and clearance of AKR/Gross
MuLV-infected cells has been demonstrated, in part through
the use of the CTL-insusceptible, variant cl.18-5 clonal line (of
the susceptible AKR.H-2b SL1 tumor), which, upon being
pulsed with the KSPWFTTL peptide, became susceptible to
lysis by antiviral CTL (19, 46). Also highlighting the importance of this intact CTL epitope, cells infected with retroviruses which have a substitution of arginine for the normal
lysine at position 1 of this epitope, such as the B-ecotropic
helper component of the LP-BM5 virus complex causing murine AIDS (8) and the Friend-Moloney-Rauscher family of
viruses (36, 46), are not efficiently recognized by AKR/Gross
MuLV-specific CTL.
AKR.H-2b mice are of the high-responder H-2b haplotype
but are unable to generate anti-AKR/Gross MuLV/KSPWFTTL-specific CTL (17, 43). Unlike B6 mice, the AKR.H-2b
strain carries and expresses the full complement of N-ecotropic
AKR/Gross endogenous proviruses. The KSPWFTTL epitope
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has previously been shown to be presented by Kb on the surface on both AKR.H-2b T and B lymphocytes (15). Despite the
expression of this immunodominant CTL epitope, AKR.H-2b
mice contain normal numbers of antiretroviral pCTL, however,
arguing against clonal deletion as the mechanism leading to
nonresponsiveness (45). In contrast, in adoptive-transfer experiments with young responder congenic AKR.H-2b:Fv1b
mice as recipients, donor AKR.H-2b CD4- and CD8-positive T
cells, as well as B cells, were specifically inhibitory (31). Such
cell transfers converted the recipient mice to an AKR/Gross
MuLV-specific CTL nonresponsive status, without affecting
minor H or allogeneic (H-2d)-specific CTL responsiveness.
Moreover, these cell subsets of viable AKR.H-2b splenocytes,
when added at the onset to in vitro restimulation cultures of
AKR/Gross MuLV-primed B6 responder cells, specifically inhibited the B6 antiviral (but not minor H or allogeneic) CTL
responses by a contact-dependent mechanism (32).
In the present study, we investigated the specific mechanism
through which AKR.H-2b splenocytes inhibit the generation of
AKR/Gross MuLV-specific CTL in vitro. Because of the fine
specificity for antiviral CTL responses (31, 32), we questioned
whether inhibition was occurring by T-cell-receptor-mediated
recognition of viral Ag-positive AKR.H-2b cells by antiviral
responder T cells, with involvement of subsequent FasL/Fas
interactions. In this way, we sought insight into the mechanistic
basis for AKR.H-2b inhibitory cell function and the antiviral
CTL nonresponsiveness of AKR.H-2b mice.
MATERIALS AND METHODS
Abbreviations used in this report. GCSA, Gross cell surface antigen; LDA,
limiting-dilution analysis; MuLV, murine leukemia virus; FasL, Fas ligand;
MLTC, mixed-lymphocyte tumor cell culture; cpm, counts per minute; Ig, immunoglobulin; B6, C57BL/6; B6.lpr, B6.MRL-Faslpr; B6.gld, B6.Smn.C3HFaslgld; Ag, antigen; MAb, monoclonal antibody; AICD, activation-induced cell
death; CTL, cytolytic T lymphocyte; pCTL, CTL precursor; minor H, minor
histocompatibility antigen; MHC, major histocompatibility complex; LPS, lipopolysaccharide; RA, 9-cis-retinoic acid; IL, interleukin; TNF-a, tumor necrosis
factor alpha; TGF-b, transforming growth factor b; APC, antigen-presenting
cell; SIV, simian immunodeficiency virus; HIV, human immunodeficiency virus.
Mice. The B6, B6.MRL-Faslpr (B6.lpr), B6.Smn.C3H-Faslgld (B6.gld), and
AKR strains of mice were obtained from Jackson Laboratory, Bar Harbor,
Maine, and were either inoculated or used as a source of splenic stimulator cells
at 6 to 9 weeks of age. The AKR.H-2b congenic mouse strain was maintained
through breeding of brother-sister pairs in the Animal Health Resource Facility,
Dartmouth Medical School. Breeding pairs were originally provided by David
Myers (Sloan Kettering Memorial Institute, New York, N.Y.).
Cell lines. The E?G2 (Gross virus-induced and GCSA1), and E/K1 (AKR
virus induced but GCSA2) tumors are of B6 (H-2b) strain origin. AKR.H-2b SL1
(SL1), a spontaneous GCSA1 tumor, was originally derived from the AKR.H-2b
congenic mouse strain. B.GV, a Gross virus-induced GCSA1 tumor, was derived
from a BALB.B (H-2b) mouse. These tumor cell lines have previously been
described in detail (16). The following tumor cell lines were procured from the
American Type Culture Collection, Rockville, Md.: P815, a methylcholanthreneinduced line derived from the DBA/2 (H-2d) strain; LB27.4 (H-2d/b), derived
from the fusion of a BALB/c lymphoma line (H-2d) to T-cell-depleted spleen
cells from a C57BL/10 (H-2b) mouse; and the highly NK-sensitive YAC-1. The
AKR.79.6 cell line (26) is H-2k. The RF33.7 T-hybridoma cell line (33) was
generously provided by Kenneth Rock (Dana Farber Cancer Institute, Boston,
Mass.). Cell lines were maintained by thrice-weekly in vitro passage in RPMI
1640 (Gibco, Grand Island, N.Y.) supplemented with 5% fetal bovine serum, 5 3
1025 M 2-mercaptoethanol, L-glutamine, and antibiotics.
Polyclonal CTL, CTL inhibition, responder cell fractionations, and Fas-Ig
blocking. 51Cr-release assays were conducted as previously described (18) to
measure CTL activity from bulk MLTC. Briefly, AKR/Gross MuLV-specific
CTL were generated through in vivo inoculation of responder mice with 106
nonsyngeneic, H-2b-matched tumor cells. At 11 to 14 days postinoculation, 107
immune spleen cells were cultured in mixed lymphocyte tumor cell cultures
(MLTC) with 2 3 105 irradiated E?G2 or SL1 tumor stimulator cells or 2 3 106
splenic stimulator cells. Following 6 days of in vitro restimulation in MLTC
medium containing RPMI 1640 supplemented with 5% fetal bovine serum,
4
L-glutamine, and antibiotics, 10 radiolabeled tumor target cells were mixed with
various numbers of effector cells (i.e., several effector-to-target-cell ratios), centrifuged, and incubated for 4 h at 37°C. At the end of this incubation, the cells
were centrifuged again, and an aliquot of cell-free supernatant was removed for
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gamma counting and data reduction. The percent specific lysis against tumor
cells is defined by the following formula: [(X-Y)/Z] 3 100%, where X 5 cpm
released by target cells incubated with effector cells, Y 5 cpm released by target
cells incubated alone, and Z 5 cpm released by the freeze-thaw of target cells
(approximately 80% of total cpm incorporated). In experiments designed to
measure inhibition in the generation of AKR/Gross MuLV-specific CTL, 2 3 106
viable AKR.H-2b spleen cells were included in the MLTC. For reconstitution
experiments, although the absolute number of responder B6 or B6.lpr CD4- and
CD8-positive T cells remained essentially constant, the number of B cells ranged
from 5 3 106 to 10 3 106. To deplete B6 or B6.lpr responder CD4- or CD8positive T lymphocytes (prior to reconstitution with an equal number of CD4- or
CD8-positive spleen cells from immune B6.lpr or B6 mice, respectively), spleen
cells were incubated with rat IgM RL172 (anti-CD4) (kindly provided by R.
Noelle, Dartmouth) or rat IgM 3.155 (anti-Lyt 2 [all alleles] derived from supernate of TIB 211 hybridoma cells) for 1 h at 4°C and then 107 splenocytes/ml
were further incubated for 1 h at 37°C in rabbit complement (Cedarlane Laboratories, Westbury, N.Y.) diluted in Cedarlane cytotoxicity medium to obtain
populations of responder lymphocytes which were enriched for either
CD42CD81 or CD41CD82 T lymphocytes, respectively. To confirm that CD4
or CD8 T-cell depletion had been accomplished, direct flow-cytometric analysis
was performed on an aliquot of CD4 or CD8 T-cell-depleted cells by using a
FACScan (Becton Dickinson) with fluorescein isothiocyanate-labeled anti-CD4
and anti-CD8 MAbs (Pharmingen, San Diego, Calif.). The efficiency of CD4 or
CD8 T-cell depletion was in the range of 93 to 96% and 97 to 100% for
experiments 1 and 2 (see Fig. 4), respectively. To block Fas/FasL interactions, a
concentrated supernatant of a blocking Fas-Ig fusion protein (49) was derived as
a secreted product of the NIH 3T3 Fas-Ig transfectant cell line, generously
provided by Philip Leder (Howard Hughes Medical Institute, Boston, Mass.). As
an independent means of verifying the presence of Fas-Ig (human IgG1 tail) in
each supernatant preparation used, indirect flow-cytometric analysis was performed with RF33.7 T hybridoma cells (33), the kind gift of Kenneth Rock. The
FasL1 RF33.7 cells were incubated with each Fas-Ig-containing supernatant
preparation and then with fluorescein isothiocyanate-labeled F(ab9)2 goat antihuman IgG heavy-plus-light chains (Jackson ImmunoResearch Laboratories,
West Grove, Pa.), and flow-cytometric analysis was performed. As a negative
control for both flow-cytometric analysis and in vitro blocking of Fas/FasL interactions, a concentrated supernatant of cultured NIH 3T3 cells was used in
parallel to Fas-Ig preparations.
Reagents used to interfere with AKR.H-2b cell-mediated inhibition. The reagents to block inhibition were added at the onset of the 6-day MLTC. Each
blocking reagent was pretested over a range of concentrations to define the
concentration which provided maximal blockade with minimal toxicity (see the
legend to Fig. 2 for the optimal concentration of each inhibitor). LPS and RA
were obtained from Sigma Chemical Co., St. Louis, Mo. Recombinant human
IL-15 was obtained from Immunex Corp., Seattle, Wash., and recombinant
murine TNF-a was obtained from Genentech Inc., South San Francisco, Calif.
Recombinant human TGF-b was the kind gift of Bradley Arrick (Dartmouth).
Determination of pCTL frequencies. The protocol for performing LDA has
been described in detail previously (44, 45). Briefly, various numbers of responder cells, 5 3 106 irradiated B6 splenic feeder cells, and 105 irradiated
E?G2 tumor cells, as a source of viral Ag, were added to RPMI 1640 supplemented with a 1:20 dilution of rat T-stim culture supplement containing concanavalin A (Collaborative Biomedical Products, Bedford, Mass.), 100 mM
methyl-a-D-mannopyranoside (Sigma), 5.4 U of IL-2 (Cetus Corp., Emeryville,
Calif.) per well, 5 3 1025 M 2-mercaptoethanol, and HEPES buffer in U-bottom
96-well cluster plates (Corning). At the end of 9 to 10 days in culture, cells from
wells were split into three equal portions and tested on 3 3 103 51Cr-labeled
target cells. E?G2 tumor cells were used as targets to score pCTL/CTL specific
for AKR/Gross virus Ag. E/K1 (viral Ag2) and YAC-1 (NK sensitive) were
used as negative control targets. Minimal estimates of pCTL/CTL frequencies
were obtained by the Poisson distribution equation as the slope of the line
relating the percent nonresponding wells (plotted on a logarithmic y axis) and the
number of input spleen cells per well (plotted on a linear x axis). The slope of the
regression line was determined with a computer and x2 minimization analysis as
described by Taswell (39). Software used for the determination of pCTL frequencies was kindly provided by Patrick Smith (Louisiana State University
School of Medicine, Shreveport, La.). This analysis yields a minimal-frequency
estimate (l/f), as well as a 95% confidence interval of the frequency estimate and
a x2 estimate of probability, with significance indicated by P . 0.05.

RESULTS
The secondary in vitro restimulation of AKR/Gross MuLVspecific CTL from B6 and B6.gld, but not B6.lpr, mice is
inhibited by AKR.H-2b splenocytes. To determine whether
FasL/Fas interactions might be involved in the down-modulation of the B6 antiviral CTL response by viable AKR.H-2b
spleen cells as previously described (32), B6, B6.lpr (Fas2),
and B6.gld (FasL2) mice were compared as responders for the
generation of AKR/Gross MuLV-specific CTL. The 6- to
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FIG. 1. B6, B6.gld, and B6.lpr mice were immunized with 106 B.GV tumor cells. At 12 days later, 107 responder spleen cells were placed in MLTC with 2 3 105
E?G2 tumor stimulator cells and/or 2 3 106 viable AKR.H-2b splenocytes, as indicated. At 6 days later, the cells were assayed for the ability to lyse 51Cr-labeled E?G2
tumor target cells. The value for spontaneous release by target cells was 12.1%. E:T, effector-to-target-cell ratio.

9-week-old B6, B6.gld, and B6.lpr mice were each capable of
eliciting vigorous AKR/Gross MuLV-specific CTL responses
(Fig. 1); this result was repeated in seven of seven experiments.
Following in vivo priming with GCSA1 B.GV tumor cells and
in vitro restimulation of primed spleen cells with irradiated
GCSA1 E?G2 (or AKR.H-2b SL1 [results not shown]) tumor
cells in MLTC, the three responder strains produced comparably high levels of antiviral CTL activity. Significantly, viable
(i.e., not irradiated or mitomycin C-treated) AKR/Gross
MuLV Ag1 AKR.H-2b spleen cells were ineffective as in vitro
stimulators for either B6 (32) or B6.gld immune spleen cells
yet could serve as efficient stimulator cells for the generation of
B6.lpr antiviral CTL (Fig. 1); this result was repeated in three
of three experiments. These results demonstrated that the ability of viable AKR.H-2b spleen cells to serve as stimulatory APC
for a secondary antiviral CTL response required that the
primed responder cells be derived from a Fas-negative strain.
To test more directly whether the AKR.H-2b spleen cells
were playing a passive role as merely an inefficient APC (for
responder cells from Fas1 mice) or might be playing an active
role in inhibiting B6 and B6.gld AKR/Gross MuLV-specific
CTL responses, “three-cell” (primed responder cell, irradiated
E?G2 tumor stimulator cell, and viable AKR.H-2b-spleen
cell) in vitro cultures were set up. The vigorous antiviral CTL
responses generated through E?G2 tumor-cell restimulation
of primed B6 (32) and primed B6.gld responder cells were
dramatically inhibited by viable AKR.H-2b cells (Fig. 1). Again

in clear contrast, addition of viable AKR.H-2b splenocytes to
MLTC containing primed B6.lpr responder cells and E?G2
tumor stimulator cells had little or no effect on CTL generation. This result was in keeping with the ability of viable
AKR.H-2b spleen cells to function as stimulatory APC for
B6.lpr antiviral CTL responses in the absence of E?G2 tumor
stimulator cells. Inhibition by AKR.H-2b cells in three-cell
MLTC of B6 and B6.gld, but not B6.lpr, antiviral CTL (repeated in six of seven experiments) demonstrated that cells in the
AKR/Gross MuLV-specific responder cell population must
have the capacity to express Fas for the antiviral CTL response
to be inhibited by viable AKR.H-2b splenocytes.
Inhibition of the generation of AKR/Gross MuLV-specific
CTL by AKR.H-2b spleen cells is blocked by an Fas-Ig fusion
protein. The requirement for responder-cell Fas expression
suggested that FasL/Fas interactions might be occurring between Fas1 B6 or B6.gld responder cells and FasL1 AKR.H-2b
“inhibitory” cells. To test this possibility, in vitro experiments
involving a blocking Fas-Ig fusion protein (49) in the three-cell
experimental protocol were performed. While there was again
dramatic inhibition of the AKR/Gross MuLV-specific CTL
response when AKR.H-2b splenocytes were included in MLTC
containing B6 or B6.gld primed responder cells and E?G2
stimulator cells, preincubation of inhibitory AKR.H-2b splenocytes with Fas-Ig fusion protein largely or completely restored
the generation of a vigorous AKR/Gross MuLV-specific CTL
response (Table 1). Therefore, and importantly, because B6.gld
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TABLE 1. Preincubation of AKR.H-2b splenocytes with Fas-Ig fusion protein blocks inhibition of antiviral CTL from immune B6 and
B6.gld responder micea
Responder
mouse strain

Secondary in vitro stimulation
Tumor cell

B6 (expt 1)

B6.gld (expt 2)

% Specific lysis
b

Fas-Ig protein present

E:T ratio

SL1

E?G2

50:1
50:1
10:1
2:1
50:1
50:1
50:1
10:1
2:1
50:1
10:1
2:1

22
23
23
22
7
23
23
21
21
3
3
0

1
80
72
44
24
1
73
75
36
64
54
24

3
86
91
71
26
3
77
79
49
77
66
30

50:1
50:1
10:1
2:1
50:1
50:1
50:1
10:1
2:1
50:1
10:1
2:1

24
23
24
24
24
22
24
25
25
25
25
26

0
53
38
11
12
4
65
37
13
65
35
13

23
55
43
15
8
1
55
42
16
56
39
18

Splenocyte

None
E?G2

None
None

2
2

E?G2
None
E?G2

AKR.H-2b
None
None

2
1
1

E?G2

AKR.H-2b

1

None
E?G2

None
None

2
2

E?G2
None
E?G2

AKR.H-2b
None
None

2
1
1

E?G2

AKR.H-2b

1

Control (ECK1)

Viral

a
B6 (experiment 1) or B6.gld (experiment 2) mice were immunized with 106 B.GV tumor cells 11 (experiment 1) or 13 (experiment 2) days before in vitro stimulation
with 2 3 105 E?G2 tumor cells without or with 2 3 106 AKR.H-2b splenocytes, as indicated. AKR.H-2b splenocytes were preincubated for 1 h at 37°C with concentrated
supernatant containing Fas-Ig fusion protein, where indicated. At 6 days later, the cells were assayed for the ability to lyse 51Cr-labeled target cells. AKR.H-2b-mediated
CTL inhibition was substantially blocked by Fas-Ig fusion protein in four of four and two of two experiments when B6 and B6.gld responder cells were used, respectively.
The values for spontaneous release by target cells ranged from 7 to 9.4% and 9.1 to 23.7% for experiments 1 and 2, respectively.
b
E:T ratio, effector-to-target-cell ratio.

responder mice are incapable of expressing FasL, functional
FasL must be expressed solely on the AKR.H-2b spleen cells.
Also of note, no increase in the generation of CTL activity was
observed under control conditions where Fas-Ig was added to
cultures containing only primed B6 responder cells plus E?G2
stimulator cells (Table 1), indicating a lack of significant FasL/
Fas-mediated inhibition independent of inhibitory AKR.H-2b
spleen cells.
Exogenous IL-15, TGF-b, RA, or LPS, but not TNF-a, restores AKR/Gross MuLV CTL generation in the presence of
inhibitory AKR.H-2b splenocytes. Previously, we demonstrated
that addition of IL-2 at the onset of in vitro restimulation
cultures partially offsets the inhibition by AKR.H-2b splenocytes of B6 AKR/Gross MuLV-specific CTL responses (32).
Here, we tested other reagents which have been described as
being inhibitors of apoptosis to see if they might also “rescue”
Fas-positive responder cells and thereby restore antiviral CTL
responsiveness. Addition of LPS (41) or RA (48) to in vitro
MLTC not only increased the ability of viable AKR.H-2b
splenocytes to serve effectively as viral Ag-positive stimulator
cells in the absence of tumor stimulator cells but also partially
restored the generation of AKR/Gross MuLV-specific CTL
lysis of E?G2 target cells following addition to three-cell in
vitro MLTC containing B6 responders, SL1 tumor stimulators,
and AKR.H-2b inhibitory cells (Fig. 2, experiment 1). In Figure
2, experiment 2, two cytokines, IL-15 (which has a similar
spectrum of activities to IL-2) and TGF-b, both of which are
antiapoptotic (34, 51), but not TNF-a, which is proapoptotic
(27), were also able to partially overcome the inhibitory effects

of AKR.H-2b splenocytes and facilitate the restoration of an
appreciable percentage of antiviral CTL production.
AKR.H-2b splenocytes inhibit AKR/Gross MuLV-specific
pCTL/CTL expansion in vitro. The above results taken together were consistent with an inhibitory mechanism in which
FasL-bearing AKR.H-2b splenocytes inhibited the expansion
of Fas-expressing AKR/Gross MuLV-specific responder
pCTL/CTL. To determine the baseline pCTL frequency of
AKR/Gross MuLV-specific pCTL, LDA of spleen cells taken
directly from B.GV primed B6 mice were performed 10 to 14
days postinoculation. In keeping with our published data (45),
we found that the pCTL frequency of immune spleen cells
from B6 mice was about 1 in 6,000 (Fig. 3). If the LDA was
instead conducted at the end of the standard in vitro MLTC
period (after immune spleen cells were restimulated with
E?G2 tumor cells to generate bulk antiviral CTL), the antiviral pCTL/CTL frequency increased to approximately 1 in 30.
This dramatic (approximately 200-fold) expansion in the number of AKR/Gross MuLV-specific pCTL/CTL correlated directly with the generation of polyclonal antiviral CTL activity
(inset in Fig. 3). In sharp contrast, inclusion of AKR.H-2b
spleen cells in three-cell MLTC resulted in a markedly decreased frequency of AKR/Gross MuLV-specific pCTL/CTL,
to 1 in 2,160, a 72-fold reduction. This decrease in antiviral
pCTL/CTL was consistent with the severe inhibition of the
polyclonal AKR/Gross MuLV-specific CTL response by the
AKR.H-2b spleen cells (inset in Fig. 3). In total, addition of
viable AKR.H-2b splenocytes inhibited the in vitro generation
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FIG. 2. Inhibition of B6 antiviral CTL restimulation is partially blocked by
the apoptosis-inhibiting agents LPS (10 mg/ml), RA (1 mg/ml), IL-15 (2 ng/ml),
and TGF-b (100 pg/ml) but not by TNF-a (10 ng/ml), (see Materials and Methods for determination of these optimal doses). B6 mice were immunized with 106
B.GV tumor cells. At 11 (experiment 1) or 12 (experiment 2) days after immunization, B6 responder cells were mixed or not mixed with viable AKR.H-2b
splenocytes, irradiated SL1 (experiment 1) or E?G2 (experiment 2) tumor
stimulator cells, and apoptosis-inhibiting agents, as indicated. Each blocking
reagent was tested in at least two independent experiments, which yielded the
same pattern of results. The values for spontaneous release by E?G2 target cells
for experiments 1 and 2 were 9.2 and 9.6%, respectively. E:T, effector-to-targetcell ratio.

of B6 AKR/Gross MuLV-specific pCTL/CTL by 10-fold in
four of four experiments.
Both Fas-expressing B6 CD8- and CD4-positive responder
spleen cells are targeted by FasL-expressing AKR.H-2b spleen
cells. To determine whether the dramatic decrease in polyclonal B6 AKR/Gross MuLV-specific CTL responsiveness
(Fig. 1 and Table 1) and correspondingly diminished pCTL/
CTL frequency (Fig. 3) were due to an AKR.H-2b cell-mediated direct inhibitory effect on responder B6 CD81 pCTL/CTL
and/or an indirect effect on responder CD41 Th cells required
for the CTL response, two related experimental approaches
were used. In the first approach (Fig. 4, experiment 1), fractionated CD41 or CD81 T lymphocytes from immunized Fasnegative B6.lpr mice were mixed with CD4- or CD8-depleted
primed B6 responder cells, respectively, at the in vitro MLTC
stage. Consistent with the data of Fig. 1, the secondary AKR/
Gross MuLV-specific CTL response of B6.lpr Fas2 “donor”
mice was not inhibitable by AKR.H-2b spleen cells (Fig. 4,
experiment 2, panel a). This characteristic allowed us to limit
the susceptibility to AKR.H-2b cell-mediated inhibition to either the CD8 or CD4 T-cell compartment. B6 responder cell
populations, depleted of either CD41 cells (experiment 1,
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panel b) or CD81 T cells (experiment 1, panel c) and reconstituted to their original numbers with immune B6.lpr CD41 or
CD81 spleen cells, respectively, generated antiviral CTL activity at levels essentially the same as that elicited by unfractionated B6 responder CTL. When the responder cell population
contained either Fas1 B6 CD81 (experiment 1, panel b) or
Fas1 CD41 (experiment 1, panel c) cells, along with the
B6.lpr-derived Fas2 counterpart T-cell subset, substantial inhibition (range, 47 to 74%) of generation of the antiviral CTL
response was noted upon addition of AKR.H-2b spleen cells in
a standard three-cell MLTC. These data suggested that FasL/
Fas-mediated inhibition of either the responder CD81 CTL or
requisite CD41 Th-cell populations could occur and form the
basis for the AKR.H-2b spleen cell-mediated inhibition of the
antiviral CTL response.
In the second approach, by reconstituting either CD4-depleted (experiment 2, panel b) or CD8-depleted (experiment 2,
panel c) primed B6.lpr (Fas2) responder cell populations with
CD41 or CD81 immune (Fas1) B6 spleen cells, respectively,
the same conclusion was reached: the B6.lpr responder CTL
response was converted to susceptibility to substantial (79 to
86%) inhibition by AKR.H-2b spleen cells when either the
CD81 or CD41 T-cell subset originated from B6 mice. These
two experimental approaches, each repeated once with essentially the same pattern of results, highlighted the importance of
not only the CD8 CTL but also the CD4 Th-cell component in
the generation of an optimal B6 AKR/Gross MuLV-specific
CTL response and demonstrated that both Fas1 responder B6
CD4 and CD8 T-cell subsets are vulnerable to inhibition by
FasL1 AKR.H-2b spleen cells.
Inhibition of B6 AKR/Gross MuLV-specific CTL responses
is specific and MHC restricted. Because of our previous demonstration of the fine antigen specificity of the inhibition mediated by viable AKR.H-2b spleen cells (i.e., only AKR/Gross
MuLV, not allogeneic or minor H-specific CTL responses,
were diminished), it seemed likely that only activated Fas1
AKR/Gross MuLV-specific responder T cells would be targeted by FasL and viral Ag-positive AKR.H-2b cells, upon
MHC-restricted T-cell receptor recognition of the latter inhibitory cells by the responder T cells. Therefore, we tested
whether the inhibitory function of AKR.H-2b cells was MHC
restricted. To this end, we used, in parallel with AKR.H-2b
congenic spleen cells, AKR (H-2k) splenocytes, which share
the high-leukemic AKR genetic background, including Akvtype endogenous retrovirus expression and thus AKR/Gross
MuLV Ag positivity. Under conditions where viable
AKR.H-2b spleen cells caused a dramatic inhibition of the
anti-AKR/Gross MuLV, but not an anti-allogeneic (H-2d),
CTL response (Fig. 5a and b, respectively), as we have previously reported (32), viable AKR spleen cells were unable to
substantially inhibit the antiviral CTL response (Fig. 5c). AKR
spleen cells could serve effectively as stimulator cells for the
generation of a B6 anti-allogeneic H-2k CTL response (Fig.
5d), however, indicating their capacity to be recognized as
APC.
These results (confirmed in a second experiment) demonstrated that the interaction between the AKR.H-2b inhibitory cell
and the lymphoid responder T cell was MHC (H-2b) restricted.
DISCUSSION
Unlike the prototypic high-responder B6 strain, AKR.H-2b
congenic mice specifically fail to generate an antiviral CTL
response to AKR/Gross MuLV (17, 43). As to the mechanism
of this specific unresponsiveness, we showed preservation of
pCTL frequencies (45) but determined that AKR.H-2b CD41
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FIG. 3. Minimal estimate of the frequency of B6 pCTL/CTL specific for syngeneic GCSA1 E?G2 tumor cells. Solid arrows illustrate the kinetics of the treatment
conditions of B6 spleen cells, which included in vivo priming (of B6 mice) with 106 B.GV tumor cells, in vitro restimulation of polyclonal spleen cells with E?G2 tumor
cells without or with AKR.H-2b spleen cells, and establishment of limiting-dilution cultures of immune spleen cells (taken directly from the immunized mouse or from
MLTC wells obtained at the end point). Dashed arrows identify the results of 51Cr release assays, which include the pCTL/CTL frequency following in vivo priming
of B6 mice, bulk CTL data following polyclonal restimulation (inset), and the pCTL/CTL frequency of primed and restimulated (restim.) B6 spleen cells. The estimates
of probability as determined by x2 minimization, where significance is indicated by P . 0.05, are shown in parentheses.

and CD81 T cells, as well as B cells, each can mediate inhibition of the AKR/Gross MuLV-specific CTL response in both
in vitro (32) and in vivo (31) models, in a manner dependent on
their viral Ag positivity (32). Here we extend these findings by
showing that the AKR/Gross MuLV-specific CTL response of
immune B6 (Fas1/FasL1), but not B6.lpr (Fas2), mice can be
nearly completely inhibited by addition of AKR.H-2b splenocytes during the in vitro restimulation stage of CTL generation
(Fig. 1). These and other data obtained through the use of a
blocking Fas-Ig and several antiapoptotic reagents illustrate
that cells in the virus-specific responder cell population must
express Fas to be inhibited by FasL1 AKR.H-2b splenocytes.
These results thus implicated FasL/Fas-mediated apoptosis as
a mechanism of inhibition of the antiviral CTL response, although technical limitations did not allow us to assess the
apoptotic cell death of antiviral T cells directly. The critical
role of the viral Ag-positive AKR.H-2b spleen cells in this
apparent apoptosis was clear; the related normal regulatory
mechanism of AICD among responder cells did not seem
likely. Evidence of the lack of FasL/Fas-mediated “fratricide”

or “autologous suicide” by Fas- and FasL-expressing activated
responder T cells included the following: (i) the levels of antiAKR/Gross MuLV CTL activity generated were not consistently higher with B6.lpr and/or B6.gld then with B6 responders, and more incisively (ii) inclusion of the blocking Fas-Ig
fusion protein in MLTC containing only responder B6 cells
and E?G2 stimulator cells did not lead to increased levels of
CTL generation (Table 1). Rather, consistent with the strict Ag
and MHC-restricted specificity of the inhibition (32), the inhibitory mechanism appeared to require viral Ag and FasL to
be concomitantly expressed on AKR.H-2b cells, such that when
the AKR.H-2b cells were recognized by Fas1 antiviral T cells,
the latter were inhibited or “vetoed” (probably killed by Fasdependent apoptosis) (11, 28). Although the observed dramatic decline in the numbers of AKR/Gross MuLV-specific
pCTL/CTL was compatible with a FasL/Fas-mediated apoptosis of responder CD81 CTL, both CD81 pCTL/CTL and
CD41 Th cells were clearly shown to be susceptible to substantial inhibition by AKR.H-2b veto cells (Fig. 4). There was
some evidence, however, that the extent of inhibition was not
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FIG. 4. B6 and B6.lpr mice were immunized with 106 B.GV tumor cells. At
14 days later, B6 (experiment 1) or B6.lpr (experiment 2) responder spleen cell
populations, which were either unfractionated or CD4 or CD8 depleted, were
reconstituted to their original numbers with immune B6.lpr CD41 or CD81
(experiment 1)- or B6 CD41 or CD81 (experiment 2)-enriched spleen cells,
respectively, and mixed with E?G2 tumor stimulator cells without or with
AKR.H-2b inhibitor cells, as indicated. The effector-to-target-cell ratios shown
are 50:1 and 20:1 for experiments 1 and 2, respectively. The values for spontaneous release by E?G2 tumor target cells ranged from 5.1 to 10.8%.

as complete when only the CD4 or CD8 T-cell compartment
was Fas1 as was the inhibition when intact B6 responder cells
were used, suggesting a cumulative inhibitory effect when both
T-cell subsets are Fas1.
Veto cell-modulated decreases in antivirus-specific pCTL/
CTL have been reported in other studies, such as that by
Rammensee et al. (29), which demonstrated the capacity of
veto cells to modulate a decrease in specific pCTL in vivo.
Also, injection of anti-CD4 MAb causes Fas-mediated CD41T-cell depletion in vivo (42). Additional studies are required to
determine whether the AKR/Gross MuLV-specific pCTL/CTL
frequency of AKR.H-2b mice (45) decreases in vivo following
activation coincident with upregulation of the expression of
Fas and possibly FasL.
IL-2 (32), IL-15, and TGF-b (Fig. 2) greatly augmented but
did not completely restore the generation of the B6 antiviral
CTL response in the presence of AKR.H-2b inhibitory cells.
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FIG. 5. B6 mice were inoculated with 106 B.GV tumor cells. At 11 (experiment 1) or 12 (experiment 2) days later, 107 responder spleen cells were mixed
with 2 3 105 E?G2 or LB27.4 (H-2b/d) tumor stimulator cells, without or with
the addition of 2 3 106 viable AKR.H-2b (experiment 1) or AKR (experiment 2)
splenocytes as indicated. At 6 days later, the cells were assayed for the ability to
lyse 51Cr-labeled target cells. The values for spontaneous release by target cells
used in either experiment ranged from 4.7 to 15.5%. E:T, effector-to-target-cell
ratio.

Assuming that although both T-cell subsets can be targets for
inhibition, some CD81 T cells survive, these cytokines may
function to replace the CD41 Th1 helper function that is
required for full CTL generation but lost when these Th1 cells
are targeted for apoptosis by the veto cells. Indeed, some
studies have suggested not only that CD41 T cells are more
susceptible than CD81 T cells to FasL/Fas apoptosis but also
that Th1 cells are more vulnerable to apoptosis than are Th2
cells (30, 50). Alternatively, these cytokines and the other
agents able to partially restore CTL generation (LPS and RA)
may provide direct antiapoptotic effects to the CD41 Th1
and/or the CD81 pCTL/CTL. For example, downmodulation
in Bcl-2 expression may be blocked by exogenous IL-2 in vitro
in our system, consistent with the study performed by Adachi
et al. in which IL-2 rescued cells from apoptosis by promoting
continued Bcl-2 expression (1).
Based on our in vitro experiments, however, the evidence is
clearly suggestive that AKR.H-2b veto cells exhibit unidirectional apoptotic immunosuppression of the very virus-specific
T lymphocytes required for viral clearance and thereby promote virus escape from immune system surveillance. On the
other hand, Suzuki and Fink (38) recently investigated whether
in addition to delivery of a negative apoptotic signal, FasLbearing cells might receive positive “reverse signaling” through
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FasL/Fas ligation. In this latter study, it was determined that
murine FasL expression was the initial signaling source for
proliferation of activated B6 wild-type and B6.lpr CD81 cell
lines, that CD81-T-cell proliferation was blocked by a soluble
Fas-Ig fusion protein, and that CD41 T cells were more susceptible to FasL/Fas-mediated apoptosis than were CD81
CTL. Along these lines, further studies are needed to determine whether FasL1 AKR.H-2b T lymphocytes receive positive signals following their recognition by antiviral T lymphocytes.
The early literature on FasL/Fas-mediated apoptosis highlighted the importance of FasL expression on cells found in
immunologically privileged sites, such as the eyes and testes
(12). More recently, certain tumor cells have been shown to
use a Fas-low/FasL-high phenotype as a means of escaping
immune system surveillance: for example, human melanoma
(21) and hepatocellular carcinoma (37) cells do not express
significant levels of Fas but do express high levels of FasL. In
each case, not only do the tumor cells escape CTL lysis but also
they effectively deliver a FasL “death signal” to Fas-expressing,
anti-tumor CTL when the CTL recognize class I-MHC presented tumor-specific Ag. Similarly, CD41 T cells infected with
the pj5 wild-type SIVmac32H clone have shown increased
FasL expression which correlated with the death of SIV-specific CTL (47).
It has been proposed that the decrease in the number of
CD41 T lymphocytes in HIV-infected asymptomatic patients,
which long has been considered a key indicator of subsequent
disease progression, is due to an inappropriate induction of the
apoptotic cell death program (2, 20). In a related study, Banda
et al. (4) demonstrated that CD4 could be cross-linked with
HIV glycoprotein gp120, resulting in apoptosis of the CD41
cells. To determine if CD4 cross-linking might influence Fas
expression, Desbarats et al. (9) used an MRL-lpr/lpr (Fas2)
mouse model. In this study it was determined that cross-linking
CD4 with anti-CD4 MAb correlated with an upregulation of
Fas receptor on normal but not MRL-lpr/lpr spleen cells, consistent with apoptosis via the FasL/Fas-mediated pathway.
Other studies with the HIV system have demonstrated that
Fas-expressing CD81, as well as CD41, T cells can be directly
targeted for apoptosis, although there is disagreement whether
there is a correlation between apoptosis susceptibility and disease progression (10, 14, 25). There is also evidence at odds
with a pathogenic role for FasL/Fas-mediated apoptosis in
AIDS. For example, it has been reported that peripheral blood
mononuclear cells from HIV-infected individuals do not express detectable FasL, in contrast to peripheral blood mononuclear cells from healthy control individuals (35). This abnormally low FasL expression was correlated with progression to
a more advanced disease state.
The results of numerous studies of Fas and FasL expression
on activated T-effector lymphocytes, following clearance of an
invading pathogen or model antigen, have been taken to suggest that the then obsolete effector cells are deleted by AICD
fratricide and/or autologous suicide as a means of maintaining
normal homeostasis and preventing an accumulation of unneeded cells (see, e.g., references 3, 6, and 23). In addition,
recent evidence has shown the importance of FasL expression
on several other normal, non-T-lymphocyte cell types, including murine B cells (22), thymic epithelial and thymic dendritic
cells (13), and human keratinocytes (5). Significantly, we have
found that AKR.H-2b B cells consistently express similar or
slightly higher densities of viral antigens compared to either
the CD4 or CD8 subset of AKR.H-2b T cells (15, 32) and that
these B cells can substantially inhibit AKR/Gross MuLV-specific CTL responses both in vivo and in vitro (31, 32). There-
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fore, we hypothesize that AKR.H-2b B cells, like AKR.H-2b
CD4 and CD8 T cells, may function as FasL1 veto cells to
induce apoptosis in responder T cells.
While this discussion has focused on the ability of retrovirusinfected cells to induce the apoptosis of specific immune T cells
directed against viral epitopes, it is also worth considering
strategies whereby virus-infected cells and tumors attempt to
prevent their own apoptotic cell death. Several viruses, including adenovirus, baculovirus, cowpox virus, Epstein-Barr virus,
African swine fever virus, herpesvirus, and papillomavirus,
have been reported to contain potential mechanisms for escape from immune systems surveillance via FasL/Fas interactions by encoding antiapoptotic gene products (reviewed in
references 35 and 40). In a recent study of human T-lymphocyte virus type 1, a retrovirus somewhat analogous to AKR/
Gross MuLV that also causes T-cell lymphoma/leukemia,
transgenic mice carrying the env-pX segment of human Tlymphocyte virus type 1 became more resistant to autoreactive
T cells and to anti-Fas MAb-induced apoptosis than were their
nontransgenic counterparts in an autoimmune arthropathy
model (24). These findings demonstrated that the Tax segment
of pX coded for an antiapoptotic gene product. Thus, by protecting virus-infected host cells from apoptosis, a virus may
promote self-survival. Whether in addition to inducing apoptosis of responding T cells, AKR/Gross MuLV has sequences
which may code for antiapoptotic gene products that spare
infected cells has not been determined.
In summary, this report, to our knowledge, is the first to
demonstrate that MuLV-infected cells may interfere with viral
clearance by using the FasL/Fas apoptotic pathway to eliminate immune T lymphocytes via viral Ag-positive veto cells.
With this study as a foundation, additional experiments must
be performed to further probe the complex interactions between immune lymphocytes and AKR/Gross MuLV-infected
cells, the challenging goal being to specifically block detrimental veto cell-mediated FasL/Fas-mediated apoptosis while
maintaining AICD that is required for homeostasis.
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